Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma

References

• Alfieri S, Granata R, Bergamini C, Resteghini C, Bossi P, Licitra LF, Locati LD. 2017. Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm? Oral Oncol. 66:58–63.
   PubMed Web of Science ®Google Scholar
• Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, et al. 2017. Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer. Cancer Discov. 7(3):264–76. doi:https://doi.org/10.1158/2159-8290.CD-16-0828.
   PubMed Web of Science ®Google Scholar
• Blass E, Ott P. 2021. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 18(4):215–29.
   PubMed Web of Science ®Google Scholar
• Boon E, van Boxtel W, Buter J, Baatenburg de Jong RJ, Van Es RJJ, Bel M, Fiets E, Oosting SF, Slingerland M, Hoeben A, et al. 2018. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands. Head Neck. 40(3):605–13. doi:https://doi.org/10.1002/hed.25035.
   PubMed Web of Science ®Google Scholar
• Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie W-R, Hildebrand WH, Mardis ER, et al. 2015. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 348(6238):803–08. doi:https://doi.org/10.1126/science.aaa3828.
   PubMedGoogle Scholar
• Chiang C-L-L, Coukos G, Kandalaft LE. 2015. Whole tumor antigen vaccines: where are we? Vaccines. 3(2):344–72. https://doi.org/https://doi.org/10.3390/vaccines3020344.
   PubMed Web of Science ®Google Scholar
• Cohen RB, Delord J-P, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong R-L, Le Tourneau C, et al. 2018. Pembrolizumab for the treatment of advanced salivary gland carcinoma. Am J Clin Oncol. 41(11):1083–88. https://doi.org/https://doi.org/10.1097/COC.0000000000000429.
   PubMed Web of Science ®Google Scholar
• Darvin P, Toor SM, Sasidharan Nair V, Elkord E. 2018. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 50(12):1–11.
   PubMed Web of Science ®Google Scholar
• El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. 2017. WHO classification of head and neck tumours. 4th ed. IARC publications - Google Scholar [WWW Document]. [accessed 2020 Jul 10]. https://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=AK+El%E2%80%90Naggar&author=JKC+Chan&author=JR+Grandis&author=T+Takata&author=PJ+Slootweg&title=WHO+Classification+of+Head+and+Neck+Tumours.
   Google Scholar
• Garg AD, Vara Perez M, Schaaf M, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. 2017. Trial watch: dendritic cell-based anticancer immunotherapy. OncoImmunology. 6(7):e1328341.
   PubMed Web of Science ®Google Scholar
• Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft LE. 2020. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat Rev Drug Discov. 19(9):635–52.
   PubMed Web of Science ®Google Scholar
• Holmström MO, Ahmad SM, Klausen U, Bendtsen SK, Martinenaite E, Riley CH, Svane IM, Kjær L, Skov V, Ellervik C, et al. 2019. High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals. Blood Cancer J. 9(2):1–14. doi:https://doi.org/10.1038/s41408-018-0166-4.
   Google Scholar
• Holmström MO, Andersen MH. 2020. Healthy donors harbor memory T cell responses to RAS neo-antigens. Cancers. 12(10):3045.
   Web of Science ®Google Scholar
• Kadowaki S, Yatabe Y, Hirakawa H, Komori A, Kondoh C, Hasegawa Y, Muro K. 2013. Complete response to trastuzumab-based chemotherapy in a patient with human epidermal growth factor receptor-2-positive metastatic salivary duct carcinoma ex pleomorphic adenoma. Case Rep Oncol. 6(3):450–55.
   PubMedGoogle Scholar
• Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, et al. 2019. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 565(7738):234–39. doi:https://doi.org/10.1038/s41586-018-0792-9.
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Chan HT, Nakamura Y. 2018. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Sci. 109(3):542–49.
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Park J-H, Inoue H, Husain A, Olugbile S, Zewde M, Nakamura Y, Vigneswaran WT. 2017. Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. OncoImmunology. 6(2):e1278330.
   PubMed Web of Science ®Google Scholar
• Linxweiler M, Kuo F, Katabi N, Lee M, Nadeem Z, Dalin MG, Makarov V, Chowell D, Dogan S, Ganly I, et al. 2020. The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin Cancer Res Off J Am Assoc Cancer Res. 26(12):2859–70. doi:https://doi.org/10.1158/1078-0432.CCR-19-3758.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. 2016. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 351(6280):1463–69. doi:https://doi.org/10.1126/science.aaf1490.
   PubMed Web of Science ®Google Scholar
• Morisaki T, Hirano T, Koya N, Kiyota A, Tanaka H, Umebayashi M, Onishi H, Katano M. 2014. NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors. Anticancer Res. 34(8):4529–38.
   PubMed Web of Science ®Google Scholar
• Morisaki T, Hikichi T, Onishi H, Takafumi M, Kubo M, Hirano T, Yoshimura S, Kiyotani K, Nakamura Y. 2020. Intranodal administration of neoantigen peptide-loaded dendritic cell vaccine elicits epitope-specific T cell responses and clinical effects in a patient with chemorefractory ovarian cancer with malignant ascites. Immunol Invest. 1–18. doi:https://doi.org/10.1080/08820139.2020.1778721
   PubMed Web of Science ®Google Scholar
• Nakaguro M, Tada Y, Faquin WC, Sadow PM, Wirth LJ, Nagao T. 2020. Salivary duct carcinoma: updates in histology, cytology, molecular biology, and treatment. Cancer Cytopathol. 128(10):693–703.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. 2017. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547(7662):217–21. doi:https://doi.org/10.1038/nature22991.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, et al. 2020. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 183(2):347–362.e24. doi:https://doi.org/10.1016/j.cell.2020.08.053.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12(4):252–64.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. 2015. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 33(17):1974–82.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al. 2017. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 547(7662):222–26. doi:https://doi.org/10.1038/nature23003.
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, et al. 2019. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 51(2):202–06. doi:https://doi.org/10.1038/s41588-018-0312-8.
   PubMed Web of Science ®Google Scholar
• Saxena M, Bhardwaj N. 2018. Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer. 4(2):119–37.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Scheper W, Kvistborg P. 2018. Cancer neoantigens. Annu Rev Immunol. 37(1):173–200.
   PubMedGoogle Scholar
• Schumacher TN, Schreiber RD. 2015. Neoantigens in cancer immunotherapy. Science. 348(6230):69–74.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. 2015. The future of immune checkpoint therapy. Science. 348(6230):56–61.
   PubMed Web of Science ®Google Scholar
• Sood S, McGurk M, Vaz F. 2016. Management of salivary gland tumours: United Kingdom national multidisciplinary guidelines. J Laryngol Otol. 130(Suppl. S2):S142–S149.
   PubMedGoogle Scholar
• Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, Kroemer G, Galluzzi L, Garg AD. 2019. Trial watch: dendritic cell vaccination for cancer immunotherapy. OncoImmunology. 8(11):1638212.
   PubMed Web of Science ®Google Scholar
• Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. 2014. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 30(23):3310–16.
   PubMed Web of Science ®Google Scholar
• Zappasodi R, Merghoub T, Wolchok JD. 2018. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 33(4):581–98.
   PubMed Web of Science ®Google Scholar